Proof of Concept study for ERC NIPD discovered biomarkers
Scientific and medical evidence indicate that non-invasive prenatal testing, known as non-invasive prenatal testing (NIPT), is a safer alternative to invasive tests that might put the pregnancy at risk. Modern NIPT examine traces...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
Methyl-ddPCR NIPT
Proof of Concept study for the development of methylation ba...
150K€
Cerrado
ANGELab
A New GEnetic LABoratory for non invasive prenatal diagnosis
11M€
Cerrado
NIPD
A Novel Non Invasive Prenatal Diagnosis for Genetic Disorder...
3M€
Cerrado
PTQ-12-05687
Aplicación de tecnologías de secuenciación masiva al análisi...
69K€
Cerrado
PTQ-08-01-06836
Diseño y optimización del análisis genómico mediante microar...
68K€
Cerrado
PTQ-08-01-06852
Diseño y optimización del análisis genómico mediante microar...
101K€
Cerrado
Información proyecto mR-NIPD
Duración del proyecto: 18 meses
Fecha Inicio: 2016-11-21
Fecha Fin: 2018-05-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Scientific and medical evidence indicate that non-invasive prenatal testing, known as non-invasive prenatal testing (NIPT), is a safer alternative to invasive tests that might put the pregnancy at risk. Modern NIPT examine traces of fetal DNA in the maternal bloodstream to determine whether the fetus is at risk of chromosomal abnormalities such as, but not limited to, Down syndrome (trisomy 21), Patau syndrome (trisomy 13) and Edward’s syndrome (trisomy 18). In this ERC Proof of Concept Grant (mR-NIPD), we anticipate to correlate already discovered DNA biomarkers of the ERC NIPD (funded ERC) with biomarkers in mRNA transcripts. The method, directly related to the currently funded ERC, will use m6A-specific methylated mRNA immunoprecipitation combined with Next Generation Sequencing (MeRIP-Seq) on fetal and maternal mRNA samples. As a result, we aim to increase the number of fetal specific biomarkers and provide a novel, cost-effective non-invasive prenatal test that will be accessible to all pregnant women independent from social and economic status